151 related articles for article (PubMed ID: 2565749)
21. Repeated treatment with (-)-sulpiride plus a low dose of SCH 23390 displays wider neuroleptic activity without inducing dopaminergic supersensitivity.
Dall'Olio R; Gandolfi O; Roncada P; Vaccheri A; Montanaro N
Psychopharmacology (Berl); 1990; 100(4):560-2. PubMed ID: 1969667
[TBL] [Abstract][Full Text] [Related]
22. Effects of antipsychotic drugs on the long-term effects of amphetamine on nigro-striatal dopamine neurons in iprindole-treated rats.
Steranka LR
Naunyn Schmiedebergs Arch Pharmacol; 1984 Mar; 325(3):198-204. PubMed ID: 6145099
[TBL] [Abstract][Full Text] [Related]
23. Influence of typical and atypical antipsychotics on neuropeptide Y-like immunoreactivity and NPY mRNA expression in rat striatum.
Obuchowicz E; Turchan J
Neuropeptides; 1998 Oct; 32(5):473-80. PubMed ID: 9845010
[TBL] [Abstract][Full Text] [Related]
24. Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum.
Rothblat DS; Schneider JS
Neurosci Lett; 1997 Jun; 228(2):119-22. PubMed ID: 9209113
[TBL] [Abstract][Full Text] [Related]
25. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding.
Pierce RC; Rowlett JK; Bardo MT; Rebec GV
Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684
[TBL] [Abstract][Full Text] [Related]
26. Multiple amphetamine injections reduce the release of ascorbic acid in the neostriatum of the rat.
Kamata K; Wilson RL; Alloway KD; Rebec GV
Brain Res; 1986 Jan; 362(2):331-8. PubMed ID: 3942882
[TBL] [Abstract][Full Text] [Related]
27. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems.
Sonsalla PK; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1986 Sep; 238(3):932-7. PubMed ID: 2943891
[TBL] [Abstract][Full Text] [Related]
28. Haloperidol and clozapine: differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatment.
Hu XT; Wang RY
Brain Res; 1989 May; 486(2):325-33. PubMed ID: 2786442
[TBL] [Abstract][Full Text] [Related]
29. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
Wardas J; Pietraszek M; Ossowska K; Wolfarth S
Pol J Pharmacol; 1995; 47(4):349-53. PubMed ID: 8616516
[TBL] [Abstract][Full Text] [Related]
30. Crus cerebri lesions abolish amphetamine-induced ascorbate release in the rat neostriatum.
Wilson RL; Kamata K; Bigelow JC; Rebec GV; Wightman RM
Brain Res; 1986 Apr; 370(2):393-6. PubMed ID: 3518863
[TBL] [Abstract][Full Text] [Related]
31. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
32. Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes.
Reuss B; Unsicker K
Mol Cell Neurosci; 2001 Aug; 18(2):197-209. PubMed ID: 11520180
[TBL] [Abstract][Full Text] [Related]
33. Lateral hypothalamus-zona incerta region as an output station for the catalepsy induced by the blockade of striatal D1 and D2 dopamine receptors.
Ossowska K; Wardas J; Golembiowska K; Wolfarth S
Brain Res; 1990 Jan; 506(2):311-5. PubMed ID: 2154287
[TBL] [Abstract][Full Text] [Related]
34. Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels in the rat striatum.
Fage D; Scatton B
Eur J Pharmacol; 1986 Oct; 129(3):359-62. PubMed ID: 2877889
[TBL] [Abstract][Full Text] [Related]
35. Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons.
Wood PL; McQuade PS; Etienne P; Lal S; Nair NP
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):765-8. PubMed ID: 6141617
[TBL] [Abstract][Full Text] [Related]
36. Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats.
Iorio LC; Cohen M; Coffin VL
J Pharmacol Exp Ther; 1991 Jul; 258(1):118-23. PubMed ID: 1830098
[TBL] [Abstract][Full Text] [Related]
37. The amphetamine conditioned place preference: differential involvement of dopamine receptor subtypes and two dopaminergic terminal areas.
Hiroi N; White NM
Brain Res; 1991 Jun; 552(1):141-52. PubMed ID: 1833032
[TBL] [Abstract][Full Text] [Related]
38. Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations.
Costall B; Naylor RJ
Br J Pharmacol; 1995 Dec; 116(7):2989-99. PubMed ID: 8680734
[TBL] [Abstract][Full Text] [Related]
39. Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens.
Compton DR; Johnson KM
J Pharmacol Exp Ther; 1989 Feb; 248(2):521-30. PubMed ID: 2918468
[TBL] [Abstract][Full Text] [Related]
40. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action.
Meltzer HY; Zhang Y; Stockmeier CA
Eur J Pharmacol; 1992 May; 216(1):67-71. PubMed ID: 1388121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
